Cargando…
Antitumor Effects of PRIMA-1 and PRIMA-1(Met) (APR246) in Hematological Malignancies: Still a Mutant P53-Dependent Affair?
Because of its role in the regulation of the cell cycle, DNA damage response, apoptosis, DNA repair, cell migration, autophagy, and cell metabolism, the TP53 tumor suppressor gene is a key player for cellular homeostasis. TP53 gene is mutated in more than 50% of human cancers, although its overall d...
Autores principales: | Menichini, Paola, Monti, Paola, Speciale, Andrea, Cutrona, Giovanna, Matis, Serena, Fais, Franco, Taiana, Elisa, Neri, Antonino, Bomben, Riccardo, Gentile, Massimo, Gattei, Valter, Ferrarini, Manlio, Morabito, Fortunato, Fronza, Gilberto |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7827888/ https://www.ncbi.nlm.nih.gov/pubmed/33430525 http://dx.doi.org/10.3390/cells10010098 |
Ejemplares similares
-
Heterogeneity of TP53 Mutations and P53 Protein Residual Function in Cancer: Does It Matter?
por: Monti, Paola, et al.
Publicado: (2020) -
Variability in functional p53 reactivation by PRIMA-1(Met)/APR-246 in Ewing sarcoma
por: Aryee, D N T, et al.
Publicado: (2013) -
Improvement of epidermal covering on AEC patients with severe skin erosions by PRIMA-1(MET)/APR-246
por: Aberdam, Edith, et al.
Publicado: (2020) -
PRIMA-1 and PRIMA-1(Met) (APR-246): From Mutant/Wild Type p53 Reactivation to Unexpected Mechanisms Underlying Their Potent Anti-Tumor Effect in Combinatorial Therapies
por: Perdrix, Anne, et al.
Publicado: (2017) -
Time to first treatment and P53 dysfunction in chronic lymphocytic leukaemia: results of the O-CLL1 study in early stage patients
por: Monti, Paola, et al.
Publicado: (2020)